Drug intelligence / Profile preview

OWP-107

Development stage: Preclinical
Lead developer: OWP Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

OWP-107 is an undisclosed small molecule drug candidate currently in preclinical development by OWP Pharmaceuticals. It is being investigated for the treatment of psychiatric disorders and is designed for oral administration. OWP Pharmaceuticals specializes in the development of improved versions of established central nervous system (CNS) medications, often utilizing the 505(b)(2) regulatory pathway to address unmet needs in epilepsy and psychiatry. As of the latest pipeline updates, the specific target and active ingredient of OWP-107 remain proprietary.

Beyond the preview

Go deeper on OWP-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OWP-107.

Explore the full profile